arrow_back Back to App

This act aims to lower drug prices by prohibiting delays in market entry of cheaper alternatives.

This act aims to increase the availability of more affordable generic and biosimilar drugs. It prohibits pharmaceutical companies from paying other companies to delay the market entry of cheaper alternatives. As a result, citizens can expect lower drug prices and greater choice, positively impacting their personal finances and access to healthcare.
Key points
Prohibits payments to delay the market entry of cheaper generic and biosimilar drugs.
Introduces financial penalties for companies violating this prohibition, discouraging unfair practices.
Aims to increase competition in the pharmaceutical market, which should lead to lower drug prices for consumers.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_2891
Sponsor: Rep. Nadler, Jerrold [D-NY-10]
Process start date: 2021-04-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Preserve Access to Affordable Generics and Biosimilars Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_2891.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-04-28.

What are the main provisions?

Key points include:

  • Prohibits payments to delay the market entry of cheaper generic and biosimilar drugs.
  • Introduces financial penalties for companies violating this prohibition, discouraging unfair practices.
  • Aims to increase competition in the pharmaceutical market, which should lead to lower drug prices for consumers.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Nadler, Jerrold [D-NY-10].

What is the latest detailed status?

The latest detailed status is: Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 28 - 13.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health Courts and Law Economy